Empaglifolzin reduces metabolic derangements such as BP (blood pressure), hyperglycemia, body weight, uric acid, increases Ht (hamtaocrit), keton bodies, and restores altered tubule-glomerular feedback, thereby protect against diabetes-induced caidio-renal injuries.

Drug induced liver injury (DILI) is a condition with wide clinical spectrum. The diagnosis represents challenge not only due to the large number of known hepatotoxic products but especially when substance involved induce damage. Empagliflozin linked several adverse effects has been convincingly associated DILI. We report case 70-year-old type 2 diabetic woman that presented gastrointestinal sym...

Abstract EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial) trial highlighted the relevance of pharmacological inhibition sodium-glucose cotransporter 2 (SGLT2) for treatment patients with type diabetes mellitus (T2DM) and/or cardiovascular disease. Although pathways through which SGLT2 inhibitors exert a beneficial effect on system are still unknown, it has been suggested tha...

BACKGROUND Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) empagliflozin in patients with type 2 diabetes mellitus who have atherosclerotic cardiovascular disease. We compared HHF and death in patients newly initiated on any SGLT-2i versus other glucose-lowering drugs in 6 countries t...

Background: Fournier’s gangrene (FG) is a rare necrotising soft tissue infection localised in the genital areas with possible dramatic outcomes. Recently, sodium glucose co-transporter-2 (SGLT2) inhibitors were identified as risk factor. Methods: We present case report of 57-year-old female patient type 2 diabetes mellitus (T2DM) treatment empagliflozin which led to development FG. Moreover, we...

Cardiovascular disease (CVD) is the leading cause of death and one of the common diabetes-related complications in patients with type 2 diabetes. After the US Food and Drug Administration issued guidelines for assessing the CVD risk of all new glucose-lowering agents for type 2 diabetes in 2008, randomized controlled CV outcome trials with new antidiabetic drugs, such as the dipeptidyl peptidas...

That was all there was. Now we have 12 class‐ es in the United States—in other countries it is about 10 or 11. That to me is wonderful; it means that we have choice and it means that we can tai‐ lor more the therapy to the individual patients that we have. Several of the drugs we have cause weight loss as a side effect: actually 2 of them, sodium ‐glucose cotransporter 2 (SGLT2) inhibi‐ tors an...

BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower glycemia by enhancing urinary glucose excretion. The physiologic response to pharmacologically induced acute or chronic glycosuria has not been investigated in human diabetes. METHODS We evaluated 66 patients with type 2 diabetes (62 ± 7 years, BMI = 31.6 ± 4.6 kg/m(2), HbA1c = 55 ± 8 mmol/mol, mean ± SD) at baseline, after a ...